Verquvo 2,5 mg, 5 mg & 10 mg Tablet
PDF Leaflet Revision Date: 12 May 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Symptomatic chronic heart failure in adults with reduced ejection fraction (< 45%) post-decompensation.
Dosage (summary)
Starting dose: 2.5 mg once daily, titrate to 10 mg once daily as tolerated.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; unknown if excreted in breast milk.
Key Drug Interactions
- Concomitant use with other sGC stimulators (e.g., riociguat) contraindicated.
- Not recommended with PDE5 inhibitors (e.g., sildenafil).
Contraindications
- Hypersensitivity to vericiguat or excipients.
- Severe renal impairment (eGFR <15 mL/min/1.73 mu00b2) or dialysis.
- Severe hepatic impairment (Child-Pugh class C).
Common side effects
- Hypotension
- Dizziness
- Nausea
- Headache
Counselling Points
- Take with food.
- Do not double doses if missed.
- Report any signs of hypotension.
Serious warnings
- Risk of symptomatic hypotension.
- Monitor blood pressure; do not initiate if SBP <100 mmHg.
Important Disclaimer
The Verquvo 2,5 mg, 5 mg & 10 mg Tablet professional information leaflet below is the property of Bayer and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
